Cargando…

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors

BACKGROUND: The association between hematologic parameters and anti-programmed death-1 (PD-1) inhibitors was generally examined without considering therapy lines and medicine types. The study was aimed to identify potential hematologic biomarkers associated with clinical outcome in patients with non...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xinmin, Wu, Xianghua, Yu, Hui, Wang, Huijie, Sun, Si, Hu, Zhihuang, Liu, Cuicui, Zhang, Junli, Shao, Yang, Wang, Jialei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631308/ https://www.ncbi.nlm.nih.gov/pubmed/36341410 http://dx.doi.org/10.3389/fimmu.2022.1003581

Ejemplares similares

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer
por: Liu, Chang, et al.
Publicado: (2022)

Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor
por: Lin, Ying, et al.
Publicado: (2023)

Targeted therapy for cisplatin‐resistant lung cancer via aptamer‐guided nano‐zinc carriers containing USP14 siRNA
por: Zhao, Xinmin, et al.
Publicado: (2023)

Correction to: Targeted therapy for cisplatin‐resistant lung cancer via aptamer‐guided nano‐zinc carriers containing USP14 siRNA
por: Zhao, Xinmin, et al.
Publicado: (2023)

Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
por: Sun, Si, et al.
Publicado: (2017)

Hormone receptor expression correlates with EGFR gene mutation in lung cancer in patients with simultaneous primary breast cancer
por: Hu, Zhihuang, et al.
Publicado: (2020)

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers
por: Fan, Rong, et al.
Publicado: (2022)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer
por: Liao, Jiatao, et al.
Publicado: (2023)

Prognostic value of hematological parameters in patients with paraquat poisoning
por: Zhou, Deng-Chuan, et al.
Publicado: (2016)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

Prognostic Value of Hematological Parameters in Oral Squamous Cell Carcinoma
por: Trevisani, Lorenzo Fernandes Moça, et al.
Publicado: (2023)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center
por: Long, Qianqian, et al.
Publicado: (2020)

Value of Hematological and Coagulation Parameters as Prognostic Factors in Acute Coronary Syndromes
por: Babes, Elena Emilia, et al.
Publicado: (2021)

The prognostic value of prognostic nutritional index in advanced cancer receiving PD‐1/L1 inhibitors: A meta‐analysis
por: Li, Pengfei, et al.
Publicado: (2022)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD‐1 inhibitor therapy
por: Fang, Qiyu, et al.
Publicado: (2022)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Prognostic value of hematological parameters in patients with acute myocardial infarction: Intrahospital outcomes
por: Monteiro Júnior, José Gildo de Moura, et al.
Publicado: (2018)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
por: Tang, Hui, et al.
Publicado: (2022)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer
por: Chen, Li, et al.
Publicado: (2020)

PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
por: Yu, Yinan, et al.
Publicado: (2023)

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid
por: Zhao, Xinmin, et al.
Publicado: (2011)

Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
por: Li, Jing-Hua, et al.
Publicado: (2018)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023)

Prognostic value of hematological parameters in patients undergoing esophagectomy for esophageal squamous cell carcinoma
por: Hirahara, Noriyuki, et al.
Publicado: (2016)

The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer
por: Lee, Kwan Ho, et al.
Publicado: (2018)

Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations
por: Świerzko, Anna S., et al.
Publicado: (2020)

What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
por: Wang, Qingyi, et al.
Publicado: (2021)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2018)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor
por: Liu, Guo-Ying, et al.
Publicado: (2023)

Prognostic impact of the controlling nutritional status score in patients with hematologic malignancies: A systematic review and meta-analysis
por: Lu, Chuanyang, et al.
Publicado: (2022)

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
por: Xu, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5e5n12a6m1ok3v5a3pvvanfarf